Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL354 Target Snapshot

Escherichia coli · ORGANISM · Escherichia coli

69,770Compounds
18,624Assays
33Approved Drugs
2,958.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Escherichia coli as ChEMBL target CHEMBL354. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Escherichia coli
ORGANISM · Escherichia coli
As of 2026-09-13
ChEMBL target ID
CHEMBL354
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Escherichia coli still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEscherichia coli
UniProt AccessionN/A

Escherichia coli

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Escherichia coli.

Review nameEscherichia coli
OrganismEscherichia coli
Clinical Profile

Clinical Phase Distribution

33
Approved
7
Phase III
4
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC502,639.0
KI16.0
EC50276.0
KD27.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL18925 10.52 Ki 0.03 Preclinical
CHEMBL4289275 10.4 EC50 0.04 Preclinical
CHEMBL19227 10.1 Ki 0.08 Preclinical
CHEMBL376180 10.05 Ki 0.09 Clinical
CHEMBL405688 9.54 Kd 0.29 Preclinical
CHEMBL88042 9.43 Kd 0.37 Preclinical
CHEMBL315278 9.37 Kd 0.43 Preclinical
CHEMBL86476 9.28 Kd 0.53 Preclinical
CHEMBL87605 9.23 Kd 0.59 Preclinical
CHEMBL186155 9.15 IC50 0.7 Preclinical
Distribution

pChEMBL Value Distribution

336
5.0
233
5.5
146
6.0
59
6.5
42
7.0
18
7.5
19
8.0
9
8.5
8
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

LINEZOLID
CHEMBL126
Approved 2000
TRICLOSAN
CHEMBL849
Approved 1997
MEROPENEM
CHEMBL127
Approved 1996
LEVOFLOXACIN
CHEMBL5315124
Approved 1996
CIPROFLOXACIN
CHEMBL8
Approved 1987
IMIPENEM ANHYDROUS
CHEMBL148
Approved 1985
CLAVULANIC ACID
CHEMBL777
Approved 1984
CEFTRIAXONE
CHEMBL161
Approved 1984
CEFOTAXIME
CHEMBL1730
Approved 1981
ETIDRONIC ACID
CHEMBL871
Approved 1977
TOBRAMYCIN
CHEMBL1747
Approved 1975
TRIMETHOPRIM
CHEMBL22
Approved 1973
KANAMYCIN
CHEMBL1384
Approved 1973
SPECTINOMYCIN
CHEMBL1167
Approved 1971
PAROMOMYCIN
CHEMBL370143
Approved 1969
DOXYCYCLINE
CHEMBL1200699
Approved 1967
AMPICILLIN
CHEMBL174
Approved 1965
ERYTHROMYCIN
CHEMBL532
Approved 1964
VANCOMYCIN
CHEMBL262777
Approved 1964
NITROFURANTOIN
CHEMBL572
Approved 1953
CHLORAMPHENICOL
CHEMBL130
Approved 1950
Assay Landscape

Assay Landscape

18,731
Total Assays
1,231
Tested Compounds
4
Assay Types
Functional — 18,343 assays, 1,231 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 17,583 1,206 5.4
assay format 742 14 5.9
cell-based format 11 11 4.0
cell membrane format 7 0
ADME — 256 assays, 41 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 225 41 4.9
assay format 31 0
Toxicity — 88 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 45 0
organism-based format 43 0
Binding — 44 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 44 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine